Overview

• Centivax’s antivenom combines two human-derived antibodies (LNX-D09, SNX-B03) with the inhibitor varespladib to target snake venoms across multiple species.
• Preclinical trials demonstrated complete protection against 13 elapid snake species and partial protection against six more in mouse models.
• The research, published in the journal Cell, represents a significant step toward addressing the global snakebite crisis, which causes up to 100,000 deaths annually.
• Dog trials in Australia are set to begin shortly, focusing on testing the antivenom’s efficacy in real-world veterinary cases of snakebite injuries.
• Researchers are now working to refine the antibody cocktail to provide broader coverage, including viperid venoms, with the goal of eventual human applications.